STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

The combination of STALICLA and Firefly Neurosciences’s machine learning platforms and know-how will further strengthen the development of precision medicine for these patients

Geneva, Switzerland27 March 2023, STALICLA SA and Firefly Neuroscience today announced a partnership to further validate EEG-based biomarkers in biologically enriched subgroups of patients with Autism Spectrum Disorder (ASD). This follows the successful completion of STALICLA’s Phase 1b clinical trial for its lead asset STP1 where EEG measurement was shown to be a powerful predictor of efficacy.

STALICLA and Firefly Neuroscience will leverage their technological platforms including the Databased Endophenotyping Patient Identification (DEPI) platform and the FDA-cleared Brain Network Analytics (BNA™) platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials, sponsored by STALICLA.

Applying BNA™ to the DEPI-driven biologically enriched subgroups of patients with ASD is expected to establish and expand EEG as a biomarker in the field of ASD. EEG measurements will reinforce the DEPI stratification capacity and prediction of treatment response in patients with a behavioral diagnosis of ASD.

STP1 is a tailored treatment candidate for ASD-Phenotype 1, the first DEPI-enriched subgroup of patients. STP1 positive target engagement was demonstrated by specific EEG signal modulation in brain areas of interest.

Lynn Durham, STALICLA’s CEO & Founder, commented: “STALICLA is thrilled to partner with Firefly Neuroscience to advance an EEG-based treatment response marker in the NDD population. STALICLA will leverage its DEPI platform and Firefly Neuroscience’s technology to reinforce its leadership in precision medicine for neurodevelopmental disorders with rapid implementation of precision EEG in our upcoming two phase 2 programs in Autism Spectrum Disorder.”

Jon Olsen, Firefly Neuroscience’s CEO, commented: “Firefly Neuroscience is excited to partner with STALICLA on the advancement of treatment for people with ASD. Using BNA™ to target sub-groups of patients for precision medicine treatment in the CNS space is a core focus for the company. The fact that BNA™ is FDA cleared and used by clinicians in the United States to support therapy decisions for people with mental disorders puts us in a very strong position to build a referral network in support of the commercialization of novel drugs and therapies for the treatment of NDD diseases.”

STALICLA has developed and validated a machine learning platform, DEPI, allowing ASD subgroup identification and precision medicine treatment candidate selection. With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients with ASD and their tailored treatments STP1 and STP2. Both STP1 and STP2 are planned to enter Phase 2 clinical trials in 2023.

Firefly Neuroscience’s BNA™ platform is a patented technology that provides an objective, quantified assessment of cognition (brain function). It measures brain function and compares it to an FDA-cleared, normative, age-matched database using proprietary AI and advanced signal processing technology. Firefly Neuroscience’s AI platform (‘Fly-AI’) will help develop future biomarkers and companion diagnostics allowing for the expansion of existing pharma collaborations and partnerships to make the development of new CNS drugs more efficient.

About STALICLA
STALICLA is a precision molecular neuroscience clinical stage biotech company, advancing the first precision medicine platform (DEPI) for patients with neurodevelopmental disorders (NDDs), and neuropsychiatric disorders.
STALICLA’s unique approach is addressing the poor construct validity of behaviourally defined disorders through its unique platform integrating molecular data with human genetic information to create testable clinical hypotheses in psychiatry and neuroscience.
With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients with Autism Spectrum Disorder (ASD) and their tailored treatments STP1 and STP2, both of which are planned to enter Phase 2 clinical trials in 2023. STP1 and STP2 hold a multi-billion market potential.
The DEPI platform has been validated in a clinical setting showing high specificity, sensitivity and positive predictive value in prospectively designed trials recalling ‘high’ responder patients to previously failed drug candidates.
STALICLA is currently preparing its next stage of growth to advance its pipelines and scale its platform.

For further information, please visit: https://stalicla.com/

About Firefly Neuroscience
Firefly Neuroscience leverages technical advances in computing and AI to deconstruct, analyze, and compare electroencephalograms (EEG), making them clinically useful for front-line clinicians to objectively measure, monitor, and manage brain function. Building on over a decade of research, the product has received FDA clearance and is commercially used in American clinics since mid-2022.
With BNA™, clinicians and their patients can now make informed, objective therapy and disease management decisions, track changes over time and improve therapy compliance. It takes the guesswork and subjectivity out of managing mental illnesses and cognitive disorders- as one can only effectively manage what can accurately be measured.
Firefly Neuroscience’s AI platform (‘Fly-AI’) has been built to develop future biomarkers and companion diagnostics (pharma) allowing for the expansion of existing pharma collaborations to bring new drugs to market. It has been used with leading companies such as Novartis, Takeda, and Purdue and is poised to revolutionize the required objective measurement for effective CNS drug development.

For further information, please visit: https://fireflyneuro.com

   Contacts

STALICLA SA
Lynn Durham, Founder & CEO
Lynn.durham@stalicla.com
Firefly Neuroscience
Jon Olsen, CEO
Jon.olsen@fireflyneuro.com
Media inquiries
Consilium Strategic Communications
stalicla@consilium-comms.com



STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

THỦ THUẬT HAY

Tuỳ biến cách sử dụng iPhone hiệu quả, thông minh hơn với Shortcuts trên iOS 12

Shortcuts là một tính năng hay trên iOS 12 nhưng ở Việt Nam ít ai sử dụng đến. Ở các thiết bị như iPhone và iPad đã lên iOS 12 thì bạn vào App Store và tải Shortcuts về máy, Shortcuts sẽ giúp bạn tuỳ biến cách sử dụng

Hướng dẫn cách copy dữ liệu trong file PDF

Foxit Reader và Adobe Reader là hai trong số nhiều công cụ có thể giúp người dùng đọc, chỉnh sửa và tạo các file với định dạng PDF khá nổi tiếng. Không chỉ có thể, chúng còn cho phép bạn copy dữ liệu từ những file PDF

Mất thẻ bảo hiểm y tế phải làm sao?Cách làm thẻ BHYT online cho bạn

Người tham gia BHYT bị mất thẻ BHYT cần phải đăng ký cấp lại. Vậy khi mất thẻ bảo hiểm y tế phải làm sao? Bài viết này sẽ hướng dẫn cách làm thẻ BHYT online cho bạn...

Những nguyên tắc không thể quên khi sử dụng pin smartphone

Những nguyên tắc sử dụng pin ngỡ như vô cùng đơn giản nhưng hầu hết người dùng đều bỏ qua, điều này đã vô tình khiến pin trên chiếc smartphone trở nên nhanh hỏng hơn. Và sau đây là danh sách các nguyên tắc bạn cần tuân

8 cách mở công cụ kết nối mạng của Windows bạn nên lưu ngay

Nếu bạn muốn giải quyết sự cố mạng, công cụ Network Connections phải là công cụ đầu tiên cần được bật để kiểm tra. Dưới đây là 8 cách khác nhau để kích hoạt công cụ này khi bạn cần.

ĐÁNH GIÁ NHANH

Mổ bụng Essential Phone: phải làm lạnh mới mở ra được, rất khó sửa, 1 điểm iFixit

Đây là một trong những chiếc điện thoại khó mở nhất mà iFixit từng gặp. Để vào được bên trong, họ đã phải làm nóng rồi làm lạnh chiếc Essential Phone rồi xài dao nạy ra nhưng vẫn chưa suy chuyển, phải nạy mạnh tới mức

Review camera Huawei nova 2i: chi tiết ảnh và tổng thể màu sắc tốt, lấy nét nhanh, bokeh đẹp

Huawei nova 2i là chiếc điện thoại nằm trong phân khúc tầm trung của Huawei, mới vừa ra mắt tại thị trường Việt Nam gần đây với mức giá rất tốt, còn tốt hơn cả giá tại thị trường Thái Lan hiện tại. Dòng sản phẩm này

Đánh giá nhanh Huawei GR5 Mini: Ngôi vương phân khúc 4 triệu

Trong phân khúc dưới 5 triệu, Honor 4C của Huawei từng gây bão torng giới yêu công nghệ bởi những ưu điểm mà nó mang lại. Và để tiếp nối thành...